Emmanuel Olamiye

Bio: Emmanuel Olamiye is a crypto market researcher and independent analyst specializing in macroeconomic trends, digital asset markets, and emerging blockchain ecosystems. His work focuses on the intersection of global financial developments and cryptocurrency market behavior, with particular attention to liquidity cycles, market sentiment, and evolving Web3 narratives. Before contributing to MEXC Industry Perspectives, Emmanuel spent years researching digital asset market structure, on-chain innovation, and early-stage blockchain infrastructure. His analytical approach combines macroeconomic context with data-driven market research, helping readers better understand the forces shaping the crypto industry. Emmanuel is particularly interested in how global economic conditions influence digital assets, as well as the long-term development of decentralized technologies and next-generation blockchain applications. His writing style emphasizes clarity, objectivity, and actionable market insights for a global crypto audience. Areas of Expertise: - Macro & Digital Asset Markets - Market Structure & Trend Analysis - Blockchain Ecosystems & Web3 Infrastructure - On-Chain Innovation - Crypto Market Narratives & Sentiment Analysis

Недавние статьи

Dangote Refinery IPO Goes On-Chain: How Solana and Base Opened Africa's Biggest Listing

Key takeaways Dangote Petroleum Refinery and Petrochemicals FZE opened its initial public offering on September 14, 2026 at ₦525 per share, selling 4.1 billion new ordinary shares for roughly 3.3% of

2026-09-17

Avalanche to Power UAE PASS Digital Vault for 12.5 Million Users, With Helicon Landing September 22

Key takeaways TDRA, the UAE's federal digital government authority, is upgrading the blockchain layer supporting the UAE PASS Digital Vault to Avalanche, the certified document store inside the

2026-09-17

CLARITY Act Fails Senate Cloture Vote: What Happens to US Crypto Market Structure Now

Key takeaways The Senate failed to invoke cloture on the motion to proceed to H.R. 3633, the Digital Asset Market Clarity Act on September 15, 2026, with the tally at 49 to 50 and one senator not

2026-09-17

What the SEC's Proposed Transfer Agent Rules Mean for Tokenized Securities

Key takeaways The SEC proposed a comprehensive rewrite of its transfer agent rules in Release No. 34-106246, File No. S7-2026-30, the first significant update in roughly four decades, with

2026-09-09

Hanwha Builds a Tokenized Securities Platform on Avalanche as South Korea's February 2027 Rules Approach

Overview South Korea is doing something few jurisdictions have attempted, which is writing tokenized securities into the existing capital markets framework. Amendments to the Electronic Securities

2026-09-09

Privacy Coins Are the Only Crypto Sector Above Bitcoin's 2025 Peak, Up 213% as Zcash Climbs to Seventh Largest

Key takeaways Published data shows privacy coins trading 213% above their level at Bitcoin's October 6, 2025 peak, making privacy the only one of ten tracked crypto sectors above that mark while

2026-09-09

Who Wins as Traditional Securities Move On-Chain? Inside the Architecture of Coinbase's Tokenized Stocks on Base

Overview Crypto has spent the better part of a decade building financial infrastructure that works extremely well on a very narrow set of assets. Stablecoins moved trillions, venues like Aerodrome

2026-08-27

LayerZero Takes Aim at the Legacy Financial System with ATLAS, a High-Performance Headless Exchange: Here's How It Works

Overview LayerZero announced ATLAS on Tuesday, August 25, 2026, describing it as a first-of-its-kind global market infrastructure that lets both open and institutional operators run trading venues

2026-08-27

What the Launch of ZCSH Actually Changes for Zcash's Liquidity as ZEC Hits an Eight-Year High

Overview Grayscale's Zcash ETF started trading on NYSE Arca, the first US exchange-traded product to offer spot exposure to a privacy-focused cryptocurrency, created by converting the Grayscale Zcash

2026-08-27

Moderna ($MRNA) Doubles on Historic Phase 3 Cancer Vaccine Results: Everything You Need to Know

Key takeaways Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint

2026-08-20

Зарегистрируйтесь и получите до 10 000 USDT бонусов

Начните свой торговый путь сегодня!

Связанные авторы

Оливер Хьюз (Oliver Hughes)